Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

NCT04032418 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Lung Non-Small Cell Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

Roswell Park Cancer Institute